Childhood Liver Disease Research Network (ChiLDReN): FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE) Study Protocol
The FORCE study, sponsored by Arbor Research Collaborative for Health, addresses a significant unmet need in pediatric hepatology by evaluating the non-invasive FibroScan™ technology for monitoring liver fibrosis in children with chronic cholestatic liver diseases. Given the limitations of liver biopsy, this study could pave the way for broader adoption of non-invasive techniques in clinical practice, potentially leading to increased market demand for FibroScan™ devices. The pediatric liver disease market is growing, driven by rising incidences of conditions like biliary atresia and Alagille syndrome. Companies involved in non-invasive liver assessment technologies may find strategic opportunities for partnerships or acquisitions based on the outcomes of this study.
Indication: Biliary Atresia
Modality: medical device
Target: Liver fibrosis assessment via non-invasive FibroScan™ technology (transient elastography).
Sponsor: Arbor Research Collaborative for Health
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Liver fibrosis assessment via non-invasive FibroScan™ technology (transient elastography).
View original source fields
Condition raw: Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
Condition normalized: Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
Modality raw: medical device
Modality normalized: medical device
Target raw: Liver fibrosis assessment via non-invasive FibroScan™ technology (transient elastography).
Target normalized: Liver fibrosis assessment via non-invasive FibroScan™ technology (transient elastography).